ELEVAI Labs Launches E-Commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in $19.7B Global Physician Dispensed Cosmeceutical Market
ELEVAI's Physician-Dispensed Skincare Products Are Now Available Direct to Consumers
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of its online E-commerce portal. The new E-commerce portal serves as a business-to-business (B2B) extension of the Company’s existing B2B relationship with physician-dispensed providers currently offering ELEVAI products in the $19.7 billion global industry.
Through the Company’s online platform, retail customers can now select a physician provider to start their personalized skincare journey and enjoy the ease and convenience of online re-ordering.
Benefits to ELEVAI with the launch of the e-commerce portal include:
- Physicians can now offer ELEVAI’s professional-grade products, having them delivered directly to patients. These same customers have the option to reorder directly from the ELEVAI E- e-commerce portal, allowing ELEVAI to share the economic benefits with physicians;
- Potential increased sales through ease of ordering, and online marketing
- Acquire potential new customers through the integration of social media and influencer campaigns, referral programs, and user reviews;
- Granular data collection is used for understanding user trends, streamlining marketing, and geo-targeting; and
- Aligns with a long-term strategy to simplify distribution operations while cutting operating costs.ELEVAI enfinity™, an at-home face serum for daily use, featuring the industry’s first and only age 0, umbilical cord-derived, stem cell exosome created through the PRExTM process, will be sold online through this portal. ELEVAI’s in-office product, ELEVAI empower™, a post-treatment serum utilizing the same exosome platform technology, will continue to be sold only through the Company’s B2B dispensed channels. ELEVAI is also currently finalizing the development of additional skincare products to be sold through its E-commerce store expected to be announced later this year.
Sales, Marketing & Distribution Infrastructure
In the United States alone, there are over 28,000 Dermatologists, Plastic Surgeons, and Med Spas. With less than 1% of the shelf space in the U.S. and less internationally, ELEVAI has enhanced its sales and distribution infrastructure in preparation for the anticipated skincare industry’s continued growth trajectory. The company recently announced unaudited 113% YoY Q4 sales growth and 75% YoY Q4 new account growth.
Additionally, with the Company’s infrastructure in place, the Company now has the ability to quickly and efficiently launch new products utilizing the same ELEVAI exosome platform technology, sold through the same e-commerce channel with minimal programming.
Dr. Jordan Plews, ELEVAI Labs CEO, expressed his enthusiasm, stating:
“As a physician-dispensed skincare line, ELEVAI believes that the purchase of ELEVAI Skincare products is best made through an authorized ELEVAI Skincare Professional. This reflects our commitment to our valued and carefully selected Dermatologists, Plastic Surgeons, and other Skincare Professionals with the medical knowledge and experience needed to guide patients on their skincare journey and maintain the fidelity of the brand. At the same time as providing a medically-guided customer journey, ELEVAI is also providing a more convenient experience for the patient all while supporting our sales and marketing initiatives. This launch is a natural progression for the Company as we build for the future success of the brand.”
Elevai Labs Inc. is a paid client of Wealthy VC.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
